Nok Therapeutics Inc.
06/03/2026 | Press release | Distributed by Public on 06/03/2026 12:39
Departure of Certain Officers (Form 1-U)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT TO REGULATION A
Date of Report (Date of earliest event reported) May 28, 2026
NOK Therapeutics, Inc.
| Florida | 99-3344253 |
2009 MacKenzie Way, Suite 100
Cranberry Township, Pennsylvania 16066
888-691-5839
Title of each class of securities issued pursuant to Regulation A:
Common Stock
Item 7. Departure of Certain Officers
On May 28, 2026, Robert Lewis, President and Principal Executive Officer, stepped down from his position as President and Director of NOK Therapeutics, Inc., effective immediately.
Mr. Lewis's departure was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
1
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| (Exact name of issuer as specified in its charter) | NOK Therapeutics, Inc. | ||
| /s/ Brian Cogley | |||
| By (Signature and Title) | Brian Cogley | ||
| Chief Financial Officer | |||
| Date: June 3, 2026 |
2
Nok Therapeutics Inc. published this content on June 03, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 03, 2026 at 18:39 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]